Sermorelin

Sermorelin’s history begins with the 1982 isolation and sequencing of human growth hormone–releasing hormone from pancreatic tumors associated with acromegaly.¹ ² This discovery allowed researchers to identify which portion of the 44-amino-acid hormone was required to stimulate pituitary growth hormone release. During the early 1980s, shorter fragments were synthesized and tested. The first 29 amino acids retained substantial biological activity, leading to development of GHRH(1-29)-NH₂, later known as sermorelin.³ ⁴ Human studies showed that the fragment could stimulate growth hormone release while providing a tool for assessing pituitary responsiveness.⁴–⁸ Sermorelin was subsequently developed for diagnostic and pediatric endocrine use. It received U.S. approval in 1997 for evaluating and treating certain forms of childhood growth hormone deficiency, then was withdrawn from the market in 2008 for commercial rather than newly identified safety reasons.⁹ Its historical importance lies in connecting the discovery of GHRH with a practical test of endogenous pituitary function. Current research-grade sermorelin should not be treated as equivalent to a regulated prescription product.

Sermorelin reproduces the active 1–29 region of GHRH and binds GHRH receptors on somatotroph cells in the anterior pituitary. Receptor activation stimulates adenylyl cyclase, increases intracellular cyclic AMP and activates signaling that supports growth hormone synthesis and release.¹⁰ The resulting growth hormone response is pulsatile rather than a direct replacement of circulating hormone. Human research found that GHRH(1-29)-based stimulation could produce discrete growth hormone pulses, reflecting the pituitary’s existing secretory capacity.⁸ Released growth hormone acts on the liver and other tissues to increase downstream IGF-1 signaling.¹¹ Because sermorelin works upstream, its response remains shaped by endogenous regulators, including inhibitory somatostatin and feedback from growth hormone and IGF-1.¹² Sermorelin therefore depends on a functioning pituitary and does not reproduce the pharmacology of recombinant growth hormone. Its short exposure produces a temporary receptor signal, making it useful for studying the timing, reserve capacity and feedback regulation of the GH–IGF-1 axis.

Sermorelin, ipamorelin and tesamorelin all influence the growth hormone axis, but they differ in structure, receptor target and evidence base. Sermorelin is a 29-amino-acid GHRH fragment that activates pituitary GHRH receptors and is historically associated with testing pituitary growth hormone reserve.¹⁰ Ipamorelin is a five-amino-acid growth hormone secretagogue that activates the ghrelin receptor, GHSR-1a. Early research emphasized its ability to stimulate growth hormone with comparatively limited ACTH and cortisol responses.¹³ Tesamorelin is a modified, full-length 44-amino-acid GHRH analog. Like sermorelin, it activates the GHRH receptor, but its N-terminal modification improves stability. It also has a distinct clinical history: a regulated tesamorelin drug is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.¹⁴ The clearest comparison is therefore pathway and development: sermorelin is the shorter classic GHRH fragment, ipamorelin uses the ghrelin-receptor pathway, and tesamorelin is a stabilized full-length GHRH analog with indication-specific clinical evidence. These differences do not make one compound universally preferable for research.